In this letter, a series of continuous modes for designing broadband high-efficiency power amplifiers (PAs) are proposed, which extend the continuous mode concept. The impedance solutions space based on these modes offer a greater freedom for realizing broadband high-efficiency PAs. To verify this theory, a high-efficiency PA over a 54.5% bandwidth from 1.6 to 2.8 GHz is designed. The simulated results show that the fundamental impedances in this PA are found to be in good agreement with the calculated ones. Moreover, this PA delivers average output power of 14.2 W with an average drain efficiency of 75.7% in the target band.

Objective. Parkinson's disease (PD) is a severe neurological disease and its risk factors remain largely unknown. A meta-analysis was carried out to investigate the relationship of overweight and obesity with PD. Methods. We used PubMed, EMBASE, and the Chinese National Knowledge Infrastructure (CNKI) databases to identify studies of associations between overweight/obesity and PD. Overweight, obesity, and PD were used as keywords, and published works were retrieved until September 30, 2013. The extracted data were classified (BMI ≥ 30, 25 ≤ BMI < 30, and BMI < 25) according to BMI values and analyzed using RevMan5.2 and Stata11.0. Results. Four cohort studies and three case-control studies were used to evaluate the association between overweight/obesity and PD, including 2857 PD patients and 5, 683, 939 cases of non-PD controls. There was a statistically significant difference between 25 ≤ BMI < 30  and BMI < 25 in the cohort study (RR = 1.17, 95% CI, 1.03–1.32,  P = 0.03), but there was no difference between BMI ≥ 30  and BMI < 25 or BMI ≥ 30  and 25 ≤ BMI < 30, where the respective RR was 1.16 and 0.84; the respective 95% CI was 0.67–2.01 and 0.61–1.15, respectively, and the P values were 0.60 and 0.28, respectively. Case-control studies showed that there was no statistical difference between any two groups. Conclusion. Meta-analysis showed that overweight might be a potential risk factor of PD. Demonstration of a causal role of overweight/obesity in PD development could have important therapeutic implications.

Purpose: Varian Halcyon is a novel machine with dual-layer leaves, single flattening filter free (FFF) energy and an enclosed bore. The purpose of this study was to compare the differences in dosimetry and plan parameters of intensity-modulated radiation therapy (IMRT) plans between the Halcyon and Trilogy accelerators. Methods and Materials: A total of 30 IMRT plans from cervical carcinoma patients were retrospectively analyzed on the Trilogy and Eclipse v13.5 treatment planning systems (TPSs). For each patient, a new plan based on Halcyon was created with the same planning parameters and optimization constraints using the Eclipse Version 15.1 TPS. To compare plan qualities, dosimetry parameters regarding planning target volume (PTV), organs at risk (OARs), monitor unit (MU) efficiency, segment size and treatment time were evaluated. Evaluation of the helical diode array system was performed with gamma-index analysis. Results: The dose distribution of the target volume of the Halcyon and Trilogy plans showed no significant difference (p > 0.05). The mean doses of rectum and both femoral heads for Halcyon plans were significantly reduced compared to those for Trilogy plans (p < 0.05). Compared to Trilogy, Halcyon increased the number of MUs from 1542.9±248.3 MU to 2514.9±328.2 MU (p = 0.00) and decreased the delivery time from 11.28±1.36 min to 3.26±0.26 min (p = 0.00). The average segment areas of Halcyon plans for proximal and distal multileaf collimators (MLCs) were 42.1 ± 31.2 cm 2 and 28.4 ± 23.7 cm 2 , respectively, and that of Trilogy plans was 27.3 ± 16.9 cm 2. The mean gamma index (3 mm/3%) results for the Halcyon and Trilogy plans were 99.41±0.26 and 99.76±0.32 (p > 0.05), respectively. Conclusions: All Halcyon treatment plans were recognized as clinically acceptable and had statistically better OAR sparing with higher delivery efficiency. The Halcyon system exhibited fast treatment delivery of IMRT with good dosimetric agreement using ArcCHECK.

General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms

Xerostomia induced by radiotherapy is a common toxicity for head and neck carcinoma patients. In this study, the deformable image registration of planning computed tomography (CT) and weekly cone‐beam CT (CBCT) was used to override the Hounsfield unit value of CBCT, and the modified CBCT was introduced to estimate the radiation dose delivered during the course of treatment. Herein, the beams from each patient's treatment plan were applied to the modified CBCT to construct the weekly delivered dose. Then, weekly doses were summed together to obtain the accumulated dose. A total of 42 parotid glands (PGs) of 21 nasopharyngeal carcinoma patients were analyzed. Doses delivered to the parotid glands significantly increased compared with the planning doses. V20, V30, V40, Dmean, and D50 increased by 11.3%, 28.6%, 44.4%, 9.5%, and 8.4% respectively. Of the 21 patients included in the study, eight developed xerostomia and the remaining 13 did not. Both planning and delivered PG Dmean for all patients exceeded tolerance (26 Gy). Among the 21 patients, the planning dose and delivered dose of Dmean were 30.6 Gy and 33.6 Gy, respectively, for patients with xerostomia, and 26.3 Gy and 28.0 Gy, respectively, for patients without xerostomia. The D50 of the planning and delivered dose for patients was below tolerance (30 Gy). The results demonstrated that the p‐value of V20, V30, D50, and Dmean difference of the delivery dose between patients with xerostomia and patients without xerostomia was less than 0.05. However, for the planning dose, the significant dosimetric difference between the two groups only existed in D50 and Dmean. Xerostomia is closely related to V20, V30, D50, and Dmean.

In the present study, we have successfully combined the biocompatible properties of chitin with the high electrical conductivity of carbon nanotubes (CNTs) by mixing them using an imidazolium-based ionic liquid as a common solvent/dispersion medium. The resulting nanocomposites demonstrated uniform distribution of CNTs, as shown by scanning electron microscopy (SEM) and optical microscopy. Fourier transform infrared spectroscopy (FTIR) and X-ray diffraction confirmed the α-crystal structure of chitin in the regenerated chitin nanocomposite scaffolds. Increased CNT concentration in the chitin matrix resulted in higher conductivity of the scaffolds. Human mesenchymal stem cells adhered to, and proliferated on, chitin-CNT nanocomposites with different ratios. Cell growth in the first 3 days was similar on all composites at a range of (0.01 to 0.07) weight fraction of CNT. However, composites at a 0.1 weight fraction of CNTs showed reduced cell attachment. There was a significant increase in cell proliferation using 0.07 weight fraction CNT composites, suggesting a stem cell enhancing function for CNTs at this concentration. In conclusion, the ionic liquid allowed the uniform dispersion of CNTs and dissolution of chitin to create a biocompatible, electrically conducting scaffold permissive for mesenchymal stem cell function. This method will enable the fabrication of chitin-based advanced multifunctional biocompatible scaffolds where electrical conduction is critical for tissue function. † A portion of this work was carried out by the National Institute of Standards and Technology (NIST), an agency of the U. S. government, and by statute is not subject to copyright in the United States. Certain commercial equipment, instruments, materials, cell culture, services, or companies are identified in this paper in order to specify adequately the experimental procedure. This in no way implies endorsement or recommendation by NIST.

The aim of the present study was to gain insight into the neuroprotection effects and mechanism of thiazolidinedione pioglitazone in both in vitro and in vivo MPP+/MPTP induced PD models. In vivo experimental results showed that oral treatment of pioglitazone resulted in significant improvements in behavior symptoms damaged by MPTP and increase in the survival of TH positive neurons in the pioglitazone intervention groups. In addition, oral treatment of pioglitazone increased the expression of peroxisome proliferator-activated receptor-γ coactivator of 1α (PGC-1α) and increased the number of mitochondria, along with an observed improvement in mitochondrial ultrastructure. From in vitro studies, 2,4-thiazolidinedione resulted in increased levels of molecules regulated function of mitochondria, including PGC-1α, nuclear respiratory factor 1 (NRF1), NRF2, and mitochondria fusion 2 (Mfn2), and inhibited mitochondria fission 1 (Fis1). We show that protein levels of Bcl-2 and ERK were reduced in the MPP+-treated group compared with the control group. This effect was observed to be reversed upon treatment with 2,4-thiazolidinedione, as Bcl-2 and ERK expression levels were increased. We also observed that levels of the apoptotic protein Bax showed opposite changes compared to Bcl-2 and ERK levels. The results from this study confirm that pioglitazone/2,4-thiazolidinedione is able to activate PGC-1α and prevent damage of dopaminergic neurons and restore mitochondria ultrastructure through the regulation of mitochondria function.

In this review paper, we summarized the automated dementia identification algorithms in the literature from a pattern classification perspective. Since most of those algorithms consist of both feature extraction and classification, we provide a survey on three categories of feature extraction methods, including the voxel-, vertex- and ROI-based ones, and four categories of classifiers, including the linear discriminant analysis, Bayes classifiers, support vector machines, and artificial neural networks. We also compare the reported performance of many recently published dementia identification algorithms. Our comparison shows that many algorithms can differentiate the Alzheimer’s disease (AD) from elderly normal with a largely satisfying accuracy, whereas distinguishing the mild cognitive impairment from AD or elderly normal still remains a major challenge.